Partnerships

AgriTech
Bioprocessing
Pharmaceuticals
Proteomics
Synthetic Biology

Multiply Labs is revolutionizing cell therapy production with ai

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins.

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins, cutting costs by up to 70%, increasing throughput, and reducing contamination ri

The Biotech Times Editorial Team  · 
Digital Health

EliseAI partners with Nextech to embed voice AI in specialty clinics

EliseAI and Nextech are co-developing deeper API integrations to bring agentic voice AI to ophthalmology, dermatology, and orthopaedic practices.
EliseAI and Nextech are co-developing deeper API integrations to bring agentic voice AI to ophthalmology, dermatology, and orthopaedic practices.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Biologics

Avaí Bio and Austrianova begin San Raffaele diabetes cell trial

The joint venture Insulinova has convened its first steering committee with OSR to evaluate encapsulated beta-cell replacement for insulin-dependent diabetes.
The joint venture Insulinova has convened its first steering committee with OSR to evaluate encapsulated beta-cell replacement for insulin-dependent diabetes.
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics
Pharmaceuticals

Profound Medical and Telix link up on PSMA-PET and MRI prostate care

The two commercial-stage companies will co-educate physicians on combining PSMA-PET imaging with Profound's MRI-guided TULSA-PRO ablation platform.
The two commercial-stage companies will co-educate physicians on combining PSMA-PET imaging with Profound's MRI-guided TULSA-PRO ablation platform.
The Biotech Times Editorial Team  · 
Synthetic Biology
AgriTech

Fieldstone Bio joins Rio Tinto mining accelerator

The synthetic biology startup will work with Rio Tinto's geologists to commercialise biosensor-based critical-mineral measurement for exploration teams.
The synthetic biology startup will work with Rio Tinto's geologists to commercialise biosensor-based critical-mineral measurement for exploration teams.
The Biotech Times Editorial Team  · 
Digital Health
Diagnostics
Bioinformatics

BioNexus secures exclusive CogniAI licence for Malaysian healthcare AI

BioNexus Gene Lab will build AI document-processing applications for Malaysia's public healthcare digitisation programme under a ten-year exclusive licence.
BioNexus Gene Lab will build AI document-processing applications for Malaysia's public healthcare digitisation programme under a ten-year exclusive licence.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Pacira grants Molteni exclusive EXPAREL rights across EU and UK

Pacira BioSciences has licensed its liposomal bupivacaine analgesic to Italian firm Molteni Farmaceutici, targeting first commercial sales in Europe by 2027.
Pacira BioSciences has licensed its liposomal bupivacaine analgesic to Italian firm Molteni Farmaceutici, targeting first commercial sales in Europe by 2027.
The Biotech Times Editorial Team  · 
Medical Devices
Digital Health
Biotech

Al Ghurair launches Trellis Health hospital network in Dubai

The UAE conglomerate's new healthcare group opens a 50-bed multi-speciality hospital in Umm Suqeim, with two further clinics due by end of
The UAE conglomerate's new healthcare group opens a 50-bed multi-speciality hospital in Umm Suqeim, with two further clinics due by end of
The Biotech Times Editorial Team  · 
Diagnostics
Genomics
Biologics

Myriad Genetics and SOPHiA GENETICS team up on prostate HRD biomarker

The two NASDAQ-listed companies will co-develop a decentralised companion diagnostic for prostate cancer genomic instability scoring, with AstraZeneca involved.
The two NASDAQ-listed companies will co-develop a decentralised companion diagnostic for prostate cancer genomic instability scoring, with AstraZeneca involved.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Rua Bioscience and PharmAla partner to supply MDMA in New Zealand

Rua Bioscience will distribute PharmAla's GMP-grade LaNeo MDMA to authorised New Zealand psychiatrists following Medsafe's September approval for PTSD treatment.
Rua Bioscience will distribute PharmAla's GMP-grade LaNeo MDMA to authorised New Zealand psychiatrists following Medsafe's September approval for PTSD treatment.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Zealand Pharma's petrelintide hits Phase 2 weight and glycaemic goals

Petrelintide cut body weight by up to 9.2% versus 2.0% on placebo in the ZUPREME-2 trial, with near-placebo gastrointestinal discontinuation rates.
Petrelintide cut body weight by up to 9.2% versus 2.0% on placebo in the ZUPREME-2 trial, with near-placebo gastrointestinal discontinuation rates.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

vTv Therapeutics wins FDA Orphan Drug tag for HPPD in sickle cell

The North Carolina biotech's oral Nrf2/Bach1 modulator HPPD has received FDA Orphan Drug Designation for sickle cell disease, backed by preclinical fetal haemoglobin
The North Carolina biotech's oral Nrf2/Bach1 modulator HPPD has received FDA Orphan Drug Designation for sickle cell disease, backed by preclinical fetal haemoglobin
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Gate Bioscience expands Lilly deal to target hard-to-drug proteins

The Brisbane biotech adds at least one new target to its Lilly collaboration, with total milestone-contingent deal value potentially exceeding $870 million.
The Brisbane biotech adds at least one new target to its Lilly collaboration, with total milestone-contingent deal value potentially exceeding $870 million.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Epcoritamab plus R-CHOP cuts DLBCL progression risk by 51% in Phase 3

Genmab and AbbVie say their EPCORE DLBCL-2 trial is the first Phase 3 bispecific study to hit a PFS endpoint in frontline diffuse large
Genmab and AbbVie say their EPCORE DLBCL-2 trial is the first Phase 3 bispecific study to hit a PFS endpoint in frontline diffuse large
The Biotech Times Editorial Team  · 
Biologics
Synthetic Biology
Bioprocessing

NorthStrive Biosciences engages Charles River for probiotic CRO work

NorthStrive Biosciences has signed a statement of work with Charles River Laboratories to characterise plasmid copy numbers in its EL-22 and EL-32 engineered
NorthStrive Biosciences has signed a statement of work with Charles River Laboratories to characterise plasmid copy numbers in its EL-22 and EL-32 engineered
The Biotech Times Editorial Team  · 
Medical Devices

Nexalin Technology signs 10-year South America distribution deal

Nexalin Technology has appointed Inovanexa as exclusive distributor for its ANVISA-approved Sync neurostimulation device across seven Latin American countries.
Nexalin Technology has appointed Inovanexa as exclusive distributor for its ANVISA-approved Sync neurostimulation device across seven Latin American countries.
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics
Pharmaceuticals

IBA to distribute ARTMS QIS cyclotron technology for theranostics

IBA will offer ARTMS's solid-target QUANTM Irradiation System to cyclotron customers worldwide, supporting local radiometal production for theranostics.
IBA will offer ARTMS's solid-target QUANTM Irradiation System to cyclotron customers worldwide, supporting local radiometal production for theranostics.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Sanofi and Regeneron expand immunology alliance with $8bn deal

Four next-generation long-acting antibodies targeting IL-13, IL-4 and IL-4Rα join the partnership that produced Dupixent, with Regeneron receiving $1bn upfront.
Four next-generation long-acting antibodies targeting IL-13, IL-4 and IL-4Rα join the partnership that produced Dupixent, with Regeneron receiving $1bn upfront.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Survodutide hits 13.1% weight loss in Phase III obesity-T2D trial

Boehringer Ingelheim's glucagon/GLP-1 dual agonist met both co-primary endpoints in SYNCHRONIZE-2, with full results published simultaneously in the New England
Boehringer Ingelheim's glucagon/GLP-1 dual agonist met both co-primary endpoints in SYNCHRONIZE-2, with full results published simultaneously in the New England
The Biotech Times Editorial Team  · 
Diagnostics
Digital Health

Hub71 and Unilabs partner to bring diagnostics to Abu Dhabi startups

Unilabs joins Hub71+ Life Sciences as an anchor partner, with live collaborations already under way with mental health and biological-age testing startups.
Unilabs joins Hub71+ Life Sciences as an anchor partner, with live collaborations already under way with mental health and biological-age testing startups.
The Biotech Times Editorial Team  · 
Subscribe to Partnerships